EU MDR 2017/745 Compliance Services

What EU MDR 2017/745 Requires

EU MDR expands regulatory obligations across the full product lifecycle. Compliance must be demonstrable through evidence, not assumed through equivalence.

Core expectations include:

• Continuous clinical evidence supporting safety and performance

• Structured technical documentation aligned to Annex II and III

• Full product lifecycle traceability through UDI and EUDAMED

• Proactive post-market surveillance and vigilance systems

• Integrated quality management system aligned to MDR expectations

For many organizations, this requires significant restructuring of existing systems, particularly when transitioning from MDD.

Why EU MDR Compliance Matters

Market Access

Without MDR compliance, devices cannot maintain or obtain CE marking. This directly impacts access to the EU market.

Regulatory Scrutiny

Notified bodies now operate with increased rigor and reduced capacity. Weak systems lead to certification delays, nonconformities, or outright rejection.

Lifecycle Accountability

MDR shifts compliance from pre-market approval to continuous lifecycle responsibility. Organizations must demonstrate ongoing control—not one-time readiness.

Organizational Risk

Regulatory delays, recertification requirements, and market withdrawal create financial and operational exposure.

Organizations with complex regulatory portfolios often align MDR compliance with broader governance structures supported by Enterprise Risk Management Consultant frameworks.

Who Must Comply

EU MDR applies to all economic operators involved in placing devices on the EU market:

• Manufacturers (EU and non-EU)

• Authorized Representatives

• Importers

• Distributors

Each role carries defined legal responsibilities related to documentation, traceability, reporting, and regulatory cooperation.

Responsibility cannot be transferred. It must be operationalized.

Core Elements of an MDR-Compliant System

Clinical Evaluation and Lifecycle Evidence

Clinical evidence must demonstrate safety and performance throughout the product lifecycle.

This includes:

• Clinical Evaluation Reports (CERs)

• Post-Market Clinical Follow-Up (PMCF)

• Ongoing data analysis and updates

• Justified equivalence claims

Organizations strengthening clinical and risk integration often align with ISO 14971 Risk methodologies to support defensible benefit-risk analysis.

Technical Documentation (Annex II & III)

Technical documentation must be complete, structured, and immediately available for review.

Key components include:

• Device description and specifications

• Design and manufacturing information

• Risk management documentation

• Verification and validation data

• PMS procedures and outputs

• Benefit-risk analysis

Weak technical files are one of the most common causes of certification delays.

Organizations often embed documentation controls within a broader Medical Device QMS to ensure sustainability beyond initial submission.

UDI and EUDAMED Integration

MDR requires full traceability through:

• Unique Device Identification (UDI)

• Economic operator registration

• EUDAMED database submissions

• Vigilance reporting systems

UDI impacts labeling, ERP systems, supply chain control, and technical documentation structure. This is a system-level decision—not a labeling update.

Post-Market Surveillance and Vigilance

MDR requires proactive, data-driven surveillance systems.

This includes:

• Documented PMS plans

• Active data collection and analysis

• Vigilance reporting of incidents

• Periodic Safety Update Reports (PSURs)

• Trend reporting and corrective actions

Organizations transitioning from reactive PMS models must build structured surveillance programs supported by risk-based methodologies.

Quality Management System Alignment

A robust quality management system aligned with MDR expectations is essential.

This includes:

• Lifecycle planning and control

• Supplier qualification and monitoring

• Risk management integration

• CAPA systems

• Internal audit

• Management review

Most organizations achieve this through alignment with ISO 13485 Consultant Services to ensure MDR requirements are embedded operationally.

Labeling and Instructions for Use

Labeling must meet strict regulatory requirements, including:

• Compliance with Annex I safety and performance requirements

• Clear and accurate intended use

• Multilingual considerations

• UDI integration

• Disclosure of residual risks

Labeling errors are a frequent source of nonconformity during notified body review.

High-Risk Device Oversight

Class III and implantable devices face heightened regulatory scrutiny, including:

• Expert panel review

• Pre-market consultation

• Expanded clinical requirements

• Increased post-market obligations

Regulatory strategy for these devices must be defined early and maintained continuously.

EU MDR Compliance Consulting Services

Wintersmith Advisory supports medical device organizations through structured, audit-ready MDR implementation and remediation.

MDR Gap Assessments

We evaluate current systems against MDR requirements to identify:

• Documentation gaps

• Clinical evidence weaknesses

• PMS deficiencies

• Traceability limitations

• QMS misalignment

Findings are prioritized based on regulatory risk and certification impact.

Technical Documentation Development

We support development and remediation of:

• Technical files (Annex II & III)

• Clinical evaluation documentation

• Risk management files

• PMS and PMCF documentation

UDI and EUDAMED Strategy

We support:

• UDI assignment and integration

• Labeling updates

• ERP and traceability alignment

• EUDAMED registration workflows

QMS Integration and Enhancement

We design and strengthen quality systems aligned to MDR expectations through ISO 13485 Certification Consultants and structured system integration.

PMS and PMCF Program Design

We develop proactive surveillance systems that support ongoing regulatory compliance and lifecycle evidence expectations.

Notified Body Readiness

We prepare organizations for notified body review through:

• Internal readiness assessments

• Documentation review

• Gap remediation

• Audit preparation aligned with ISO Internal Audit Services

How Wintersmith Advisory Approaches MDR Compliance

We approach MDR as a systems integration problem—not a documentation exercise.

Our focus is on:

• Building defensible clinical and technical evidence

• Strengthening documentation structure and accessibility

• Integrating risk management across lifecycle stages

• Establishing proactive post-market systems

• Aligning QMS governance with regulatory expectations

• Preparing organizations for notified body scrutiny

For organizations operating across multiple regulatory frameworks, integration with Multi-Standard ISO Solutions reduces duplication and improves system coherence.

Start Strengthening EU MDR Compliance

EU MDR compliance is continuous. It is not achieved once and maintained passively.

If your organization is preparing for EU market entry, notified body review, or MDR remediation, the next step is a structured evaluation of how your system performs under regulatory expectations.

Wintersmith Advisory provides disciplined, audit-ready MDR consulting designed to protect timelines, maintain market access, and strengthen regulatory confidence.

If You’re Also Evaluating…

Organizations navigating EU MDR often evaluate:

• ISO 13485 Consultant Services

• ISO 14971 Risk

• ISO 13485 Certifications

• FDA QMSR Consultant

• 21 CFR 820 QSR FDA

These frameworks are frequently addressed together to build an integrated and defensible global medical device compliance system.